Human C1q R1 / CD93 Protein
- Known as:
- Human C1q R1 / CD93 Protein
- Catalog number:
- C11-H5228
- Product Quantity:
- 1mg
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Human C1q R1 / CD93 Protein
Related genes to: Human C1q R1 / CD93 Protein
- Gene:
- CD93 NIH gene
- Name:
- CD93 molecule
- Previous symbol:
- MXRA4, C1QR1
- Synonyms:
- C1qRP, C1qR(P), dJ737E23.1, CDw93, ECSM3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 2001-12-05
- Date modifiied:
- 2015-08-24
Related products to: Human C1q R1 / CD93 Protein
Related articles to: Human C1q R1 / CD93 Protein
- Glioblastoma (GBM) is the most aggressive type of intracranial malignant tumor, known for its extremely poor prognosis. Lactylation, a newly identified post-translational modification, has been linked to tumorigenesis, though its specific role in GBM remains unclear. This study aims to integrate single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq) data to create a novel prognostic model for GBM, focusing on lactylation-related factors. - Source: PubMed
Publication date: 2026/06/26
Wang BiaoAn YangfangShu YuansenCheng XiaopingChen XuXiangZhang XiezhuoCheng Zhaorui - Defects in the acquisition of oocyte developmental competence during the maturation process causes subfertility or infertility in animals and humans. Understanding the regulatory mechanisms of oocyte maturation is essential for reproductive biology and medicine. Follicular fluid (FF) is an important microenvironment governing oocyte maturation. - Source: PubMed
Publication date: 2026/06/22
Zhao HuaxingHe XiaohuaShi JunsongWu XiaoLiang YalinWang XingwangAo ZhengZhang XianjunZhang YuxingLi YananZhang YiqianDong YazhengPeng JingfengHou YunfeiZhou RongZeng FangHong LinjunGu TingYang HuaqiangYang JieXu ZhengHuang SixiuCai GengyuanLi ZicongWu Zhenfang - While targeting angiogenesis represents a key therapeutic strategy in several pathological contexts, it comes with significant challenges associated with therapeutic efficacy and drug resistance. Therefore, developing novel, more effective and durable therapeutic modalities is paramount. We have previously reported that antibody-mediated inhibition of CD93, a vascular endothelial cell surface glycoprotein, can inhibit angiogenesis. Here, we describe a novel strategy to efficiently inhibit CD93 expression in cells, based on the targeted degradation of CD93 mRNA using acting hammerhead ribozymes. To pinpoint single-stranded regions in CD93 mRNA that are amenable to ribozyme targeting in living cells, we performed RNA secondary structure mapping via targeted DMS-MaPseq analysis. Next, since exogenous hammerhead ribozymes are easily degraded and lose catalytic activity when expressed in living cells, we developed a novel scaffold RNA based on short stems from the 3' UTR of histone mRNAs to stabilize the active ribozyme structure and promote the CD93 cleavage under physiological conditions. Ectopic expression of these engineered ribozymes in primary endothelial cells resulted in efficient inhibition of CD93 expression, cell migration, and formation of tube-like structures in functional assays. Collectively, our data provides the proof-of-concept for the use of ribozyme-based therapeutics for the treatment of neovascular pathologies. - Source: PubMed
Publication date: 2026/05/25
Perrone Cosimo DamianoRaucci LuisaPapini SaraTosi Gian MarcoGalvagni FedericoOlivucci MassimoIncarnato DannyOrlandini Maurizio - Chronic myeloid leukemia stem cells (LSCs) drive disease initiation, persistence, and relapse. To improve LSC-based prognostication and patient stratification, we evaluated six LSC markers (CD26, CD25, IL1-RAP, CD56, CD93, and CD69) using a single-tube analysis of CD34+CD38- cells in a cohort of 48 chronic phase chronic myeloid leukemia patients at diagnosis, month 3, or month 6. We demonstrate that these markers (including the novel marker CD69) are co-expressed, and their combination enhances LSC detection, especially during follow-up when marker expression is reduced. Furthermore, LSC data from month 3 and month 6 predict patient outcomes. We also show that quantifying residual normal hematopoietic stem cells at diagnosis enables early hematological toxicity prediction. Our findings provide technological LSC detection advancements and highlight the potential of these data for prognostic applications. - Source: PubMed
Publication date: 2026/06/11
Culen MartinRomzova MariannaSmitalova DagmarLoja TomasBusa DanielVenglar OndrejHerudkova ZdenkaKassa SamuelRadova LenkaBorsky MarekReigl TomasPlevova KarlaSmejkal JiriZackova DanielaStejskal LukasMayer Jiri - CD93, an angiogenesis-related transmembrane glycoprotein, is transcriptomically downregulated in uterine corpus endometrial carcinoma, yet circulating protein levels have not been clinically evaluated. This study aimed to evaluate serum CD93 as a diagnostic biomarker for EC and to examine its association with clinicopathological parameters. In this single-center case-control study, serum CD93 concentrations were measured by enzyme-linked immunosorbent assay in 46 patients with histologically confirmed primary EC and 35 controls with histologically verified benign gynecological pathology. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed. Serum CD93 was significantly lower in EC patients than controls (median 4.55 [IQR 3.51-6.97] vs. 10.24 [7.18-12.14] ng/mL; < 0.001). In multivariable analysis adjusted for age and body mass index, lower CD93 remained independently associated with EC (OR = 0.521; 95% CI 0.061-0.720; < 0.001). ROC analysis yielded an area under the curve of 0.845 (95% CI 0.759-0.921), with 82.6% sensitivity and 74.3% specificity at a cut-off of 7.338 ng/mL. CD93 levels showed no significant association with histological subtype, grade, lymphovascular space invasion, nodal metastasis, or recurrence. Serum CD93 is significantly reduced in EC and demonstrates independent diagnostic performance, supporting its prospective validation as a non-invasive biomarker in larger multicenter cohorts. - Source: PubMed
Publication date: 2026/04/29
Bağlar İsmailŞanlıkan FatihKeles EsraKara Sahra SultanÖzdaş Cansu ErgençDönmez Yeliz ÇeçenUzun Hafize